American Century Companies Inc. Acquires 89,097 Shares of Insmed Incorporated (NASDAQ:INSM)

American Century Companies Inc. lifted its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 12.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 812,780 shares of the biopharmaceutical company's stock after purchasing an additional 89,097 shares during the quarter. American Century Companies Inc. owned 0.45% of Insmed worth $56,114,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of INSM. Steward Partners Investment Advisory LLC boosted its stake in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares in the last quarter. V Square Quantitative Management LLC lifted its holdings in shares of Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 248 shares during the last quarter. Spire Wealth Management purchased a new stake in shares of Insmed in the 4th quarter valued at $47,000. Smartleaf Asset Management LLC grew its holdings in shares of Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new position in Insmed in the 4th quarter worth $86,000.

Insmed Stock Up 0.4 %

INSM traded up $0.30 during trading on Friday, hitting $77.99. 950,343 shares of the company's stock traded hands, compared to its average volume of 2,230,931. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The company's 50 day simple moving average is $78.18 and its two-hundred day simple moving average is $74.00. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a market capitalization of $14.12 billion, a price-to-earnings ratio of -13.95 and a beta of 1.28.

Remove Ads

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The business had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Activity

In other Insmed news, insider Martina M.D. Flammer sold 3,344 shares of the company's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the completion of the sale, the insider now directly owns 102,766 shares of the company's stock, valued at approximately $6,773,307.06. This represents a 3.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sara Bonstein sold 1,066 shares of Insmed stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.72, for a total transaction of $67,925.52. Following the transaction, the chief financial officer now owns 118,863 shares in the company, valued at $7,573,950.36. This represents a 0.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 550,957 shares of company stock valued at $42,992,528 over the last three months. Insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

INSM has been the topic of a number of recent research reports. Truist Financial raised their price objective on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, February 21st. JPMorgan Chase & Co. lifted their price target on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research note on Friday, February 7th. Guggenheim reiterated a "buy" rating and issued a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Finally, Bank of America upped their price target on shares of Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat, Insmed currently has an average rating of "Moderate Buy" and a consensus price target of $94.00.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.